Amgen’s cholesterol drug patent revoked in UPC first
A European patent for a drug used in the treatment of high cholesterol has become the first to be revoked following full trial proceedings before the Unified Patent Court (UPC).
A European patent for a drug used in the treatment of high cholesterol has become the first to be revoked following full trial proceedings before the Unified Patent Court (UPC).